Faculty Presentations

Wednesday, February 21

Jeffrey J. Bednarski, MD, PhD – Siteman Kids
Presentation: Memory-like NK Cells for Treatment of Pediatric AML
Wednesday, February 21, 2024 | 11:37 AM – 12:00 PM | 221 (Meeting Level)

Iskra Pusic, MD, MSCI
Presentation: Acute & Chronic GvHD Symptom Guidance
Wednesday, February 21, 2024 | 1:30 PM – 1:55 PM | 217 (Meeting Level)

Thomas Pfeiffer, MD – Siteman Kids
Presentation: 15 Donor-Derived Memory-like NK Cells for the Treatment of Children and Young Adults with Relapsed AML Following Allo-HCT
Wednesday, February 21, 2024 | 3:45 PM – 4:00 PM | Stars at Night B1 (Ballroom Level)

Armin Ghobadi, MD
Presentation: 18 Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)
Wednesday, February 21, 2024 | 4:30 PM – 4:45 PM | Stars at Night B1 (Ballroom Level) 

Thursday, February 22

Shalini Shenoy, MD – Siteman Kids
Presentation: Allogeneic Hematopoietic Cell Transplantation
Thursday, February 22, 2024 | 7:24 AM – 7:36 AM | Stars at Night B2 & B3 (Ballroom Level)

John F. DiPersio, MD, PhD
Session: S-C5 Concurrent [ASTCT/ASGCT]: Advances in Gene Editing to Cure Human Diseases
Thursday, February 22, 2024 | 10:30 AM – 12:00 PM | Stars at Night B1 (Ballroom Level) 

Poster Presentations
Thursday, February 22, 2024 | 6:45 PM – 7:45 PM | Exhibit Hall 4a (Street Level) 

Michael Slade, MD, MSCI
146 Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma

Armin Ghobadi, MD
248 Impact of Complete Response (CR) on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Omar H. Butt, MD, PhD
279 Neuroaxonal Injury, but Not Astrocyte Injury, Is Associated with CAR T Cell Related Icans

John F. DiPersio, MD, PhD
310 Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT) 

Melissa Mavers, MD, PhD – Siteman Kids
417 Novel Subsets of Human Invariant Natural Killer T Cells, Including a Temra-like CD4-CD8- Population, Revealed through Single Cell RNA-Sequencing

Zachary D. Crees, MD
537 Motixafortide Enables Consistent, Robust Hematopoietic Stem Cell Collection (HSC) across Populations with Increased Impaired HSC Mobilization: A Sub-Group Analysis of the Genesis Study

Grace C. Powers, MSN, RN
567 Modified Suitability Review Process for High-Risk Patients Undergoing a First Allogeneic Hematopoietic Cell Transplant

Paul A. Freeman, MSN, RN, BMTCN, OCN
568 Recognizing and Retaining through the Senior Transplant Coordinator Role

Kelly Terrell, MBA, BSN, RN, BMTCN
569 From Referral to Product Infusion, What Are the Barriers to CAR T-Cell Therapy? An Academic Center’s Comprehensive Overview

Danielle Gagne, BSN, RN, MBA, BMTCN
573 Evolution of Transplant Coordinator Orientation

Carmen (Kari) Wilson, MS, PAC
620 GvHD Reporting: Optimizing Accuracy of Data Collection and Provider Compliance 

Friday, February 23

Zachary D. Crees, MD
Presentation: Viral Infections Post-Transplant and Updates in Anti-Viral Cytotoxic T-Cell Therapies
Friday, February 23, 2024 | 11:00 AM – 12:00 PM | 225 (Meeting Level)

Ashley Rumsey, MSN, APRN, AGCNS-BC, OCN, BMTCN
Presentation: Establishing and Maintaining Nursing Competency: An Endless Battle
Friday, February 23, 2024 | 3:15 PM – 3:34 PM | 225 (Meeting Level) 

John F. DiPersio, MD, PhD
Presentation: Is Stem Cell Transplantation in 2023 Just Copacetic?
Friday, February 23, 2024 | 6:00 PM – 6:20 PM | Stars at Night B2 & B3 (Ballroom Level) 

Saturday, February 24

Ashley Rumsey, MSN, APRN, AGCNS-BC, OCN, BMTCN
Session: NSG-11 (NSG) Roundtables
Saturday, February 24, 2024 | 10:30 AM – 12:00 PM | 225 (Meeting Level)